| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)NCT02606136 | Kyntra Bio | Phase 2 | Terminated | 2020-05-07Actual |
| Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaNCT02612311 | TGTX | Phase 3 | Terminated | 2023-02-22Actual |
| A Study to Evaluate SAGE-547 in Participants With Severe Postpartum DepressionNCT02614547 | SUPN | Phase 2 | Completed | 2016-06-22Actual |
| Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)NCT02618408 | SUPN | Phase 3 | Completed | 2019-09-04Actual |
| Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)NCT02618434 | SUPN | Phase 3 | Completed | 2019-11-15Actual |
| A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal ImmunizationNCT02624947 | Novavax | Phase 3 | Completed | 2018-12-28Actual |
| Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for HemodialysisNCT02644941 | HUMA | Phase 3 | Completed | 2019-05Actual |
| Tradipitant in Treatment-resistant Pruritus Associated With Atopic DermatitisNCT02651714 | Vanda Pharmaceuticals | Phase 2 | Completed | 2017-08-04Actual |
| A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304NCT02656303 | TGTX | Phase 2 | Terminated | 2022-05-26Actual |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid LeukemiaNCT02665065 | Actinium Pharmaceuticals | Phase 3 | Active not recruiting | 2022-06Actual |
| Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular MelanomaNCT02678572 | DCTH | Phase 3 | Completed | 2023-05-18Actual |
| Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721NCT02682407 | Omeros Corporation | Phase 2 | Terminated | 2020-08-25Actual |
| Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial HypertensionNCT02682511 | Cumberland Pharmaceuticals | Phase 2 | Active not recruiting | 2026-03Actual |
| Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)NCT02691182 | SUPN | Phase 3 | Terminated | 2021-05Actual |
| Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and CisplatinNCT02709512 | Polaris Group | Phase 2, Phase 3 | Completed | 2022-08-15Actual |
| Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHNCT02716246 | RARE | Phase 2, Phase 3 | Recruiting | 2029-03Estimated |
| ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor TreatmentNCT02735863 | ABVX | Phase 2 | Completed | 2017-08-30Actual |
| Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)NCT02736656 | SUPN | Phase 3 | Active not recruiting | 2026-12Estimated |
| A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell TransplantationNCT02737306 | CytoDyn, Inc. | Phase 2 | Terminated | 2021-04-14Actual |
| Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) InfectionNCT02738008 | Arrowhead Pharmaceuticals | Phase 2 | Terminated | 2016-12Actual |
| Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyNCT02742090 | TGTX | Phase 2 | Terminated | 2021-06-10Actual |
| Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic SolutionNCT02754596 | Glaukos Corporation | Phase 2 | Completed | 2017-08-01Actual |
| Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)NCT02768363 | CADL | Phase 2 | Active not recruiting | 2024-11Actual |
| Tipifarnib in Subjects With Myelodysplastic SyndromesNCT02779777 | KURA | Phase 2 | Terminated | 2018-08-28Actual |
| Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AMLNCT02781883 | Bio-Path Holdings, Inc. | Phase 2 | Recruiting | 2027-12Estimated |
| Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid LeukemiaNCT02807272 | KURA | Phase 2 | Completed | 2020-11-30Actual |
| Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer PatientsNCT02826486 | BLRX | Phase 2 | Completed | 2022-09-06Actual |
| Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With FibromyalgiaNCT02829814 | Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | 2016-09-13Actual |
| Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).NCT02831959 | NovoCure GmbH | Phase 3 | Completed | 2024-11-29Actual |
| A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel ResectionNCT02836470 | Palisade Bio | Phase 2 | Completed | 2023-09-06Actual |
Trial details
- Registry ID
- NCT02606136
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02612311
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02614547
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02618408
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02618434
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02624947
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02644941
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02651714
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02656303
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02665065
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02678572
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02682407
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02682511
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02691182
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02709512
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT02716246
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT02735863
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02736656
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02737306
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02738008
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02742090
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02754596
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02768363
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02779777
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02781883
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02807272
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02826486
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02829814
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02831959
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02836470
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.